How Many Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)’s Analysts Are Bullish?

June 18, 2018 - By Henry Gaston

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Logo

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Among 3 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Anthera Pharmaceuticals had 5 analyst reports since January 22, 2018 according to SRatingsIntel. The rating was downgraded by Piper Jaffray to “Sell” on Monday, March 12. As per Monday, January 22, the company rating was maintained by Piper Jaffray. Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rating on Tuesday, February 13. Jefferies has “Hold” rating and $1.75 target. Jefferies maintained the shares of ANTH in report on Tuesday, March 6 with “Hold” rating. Below is a list of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) latest ratings and price target changes.

12/03/2018 Broker: Piper Jaffray Rating: Sell Downgrade
06/03/2018 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain
21/02/2018 Broker: Roth Capital Rating: Buy New Target: $10 Initiates Coverage On
13/02/2018 Broker: Jefferies Rating: Hold New Target: $1.75 Maintain
22/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain

The stock decreased 4.87% or $0.015 during the last trading session, reaching $0.2931. About 600,775 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 86.78% since June 18, 2017 and is downtrending. It has underperformed by 99.35% the S&P500.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.67 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: